Cell and Gene Therapy – 2017 Philadelphia Pharmaceutical Symposium

December 2nd, 2017

Radnor Valley Country Club (555 Sproul Road, Villanova, PA 19085)

https://www.eventbrite.com/e/cell-and-gene-therapy-philadelphia-pharmaceutical-symposium-2017-tickets-39117061183

 

Breakthrough Cell and Gene Therapy (CGTApproved or on the Brink of Being Approved in 2018

 

Luxturna (Spark), the world’s 1st adeno-associated viral (AAV) vector gene therapy to correct a specific genetic mutation that causes inherited retinal diseases (IRDs).

Federico Mingozzi, Ph.D., Chief Scientific Officer, Spark Therapeutics

 

Strimvelis (GSK), the world’s 1st Hematopoietic Stem Cell Gene Therapy (HSC-GT) for adenosine deaminase deficiency (ADA-SCID).

Joseph Tarnowski, Ph.D., Senior Vice President, Cell and Gene Therapy, GlaxoSmithKline

 

 

Promising Technologies That Can Advance Future CGT Therapies

 

In vivo reprogramming for brain repair, a gene therapy technology that may have broad applications in neural repair after Alzheimer’s disease, Parkinson disease and glioma.

Gong Chen, Ph.D., Professor, Verne M. Willaman Chair in Life Sciences, Penn State University

 

Using CRISPR/CAS9 to generate universal T cells and improve adoptive immunotherapy against solid tumors.

Yangbing Zhao, M.D., Ph.D., Director, T Cell Engineering Lab (TCEL), Adjunct Associate Professor, University of Pennsylvania

 

First in man CAR strategies with expanded applicability, targeting hematological cancers, non-hematological cancers and autoimmune disorders.

Wyle Solomon, M.B.A., Chief Executive Officer, iCell Gene Therapeutics

 

 

Register before Nov. 12th to save $20+! Lunch will be provided.

https://www.eventbrite.com/e/cell-and-gene-therapy-philadelphia-pharmaceutical-symposium-2017-tickets-39117061183

 

2017-11-10T09:13:03+00:00